As a result of this finding and efficient analysis of Siglec‐1 on CD14+ cells, we started to routinely measure Siglec‐1 in all patients with COVID‐19 admitted to ICUs to distinguish between patients with high and low IFN signature to test the hypothesis of an association of IFN signature and outcome of the patients. This evidence concerns the gene CD14 and COVID-19.